Genentech, Inc.

F. Hoffmann-la Roche Ag

Robert Anthony Blake

Peter Scott Dragovich

Thomas Pillow

Ingrid Wertz

Lewis J Gazzard

Steven T Staben

Chudi Obioma Ndubaku

Richard Pastor

Vickie H Tsui

Binqing Wei

Jeremy M Murray

Till Maurer

Jason Drummond

Tracy Kleinheinz

Susan Kaufman

Kebing Yu

Lionel Rouge

Lorna Kategaya

Christine Johanna Heideker

Paola Di Lello

Jason Jake Drummond

Ingrid E Wertz

Christine Heideker

The subject matter described herein is directed to antibody-CIDE conjugates (Ab-CIDEs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.

Conjugated chemical inducers of degradation and methods of use

The present disclosure relates to compounds and salts thereof that are useful for inhibiting target polypeptides and proteins, in particular, bromodomain (e.g., BRD4) proteins. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated diseases or disorders.

Tert-butyl (s)-2-(4-(phenyl)-6H-thieno[3, 2-f][1, 2, 4]triazolo[4, 3-a] [1,4]diazepin-6-yl) acetate derivatives and related compounds as bromodomain BRD4 inhibitors for treating cancer

2-Aminopyridine compounds of Formula I are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for modulating USP7, and for treating cancer and immune disorders such as inflammation mediated by USP7. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

USP7 inhibitor compounds and methods of use

Growing community of inventors

South San Francisco, CA, United States of America

Robert Anthony Blake